Wegovy: The Weight Loss Drug That Reduces Heart Attack Risk

Novo Nordisk's weight loss drug, Wegovy, has shown promising results in reducing the risk of serious cardiovascular complications in people with obesity and heart disease. In a large-scale trial, weekly injections of Wegovy reduced the overall risk of heart attack, stroke, and death from cardiovascular causes by 20%. The drug also demonstrated a significant reduction in the risk of non-fatal heart attacks and progression to diabetes. While there were some side effects, such as gastrointestinal issues, the findings could expand insurance coverage and increase the use of Wegovy as a potentially life-saving medication for chronic obesity management.